Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of Hsp90 inhibitor AUY922 in
treating older patients with advanced solid malignancies. Hsp90 inhibitor AUY922 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth